New Study in Nature Genetics Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
RESEARCH TRIANGLE PARK, N.C. (May 15, 2014) – Metabolon, Inc., a leader in metabolomics, announced today the publication of a paper entitled “An Atlas of Genetic Influences on Human Blood Metabolites” in Nature Genetics. Co-authored by Metabolon scientists, this paper is the result of a third genome-wide association study (GWAS) that combines genomic data and metabolic profiling to gain comprehensive understanding of the human biological system and presents the most comprehensive metabolomics survey of human metabolism conducted to date.
Building on earlier work published in Nature in 2011, Metabolon, in collaboration with a team of researchers led by Pfizer, King’s College London, Helmholtz Zentrum München, Weill Cornell Medical College in Qatar and Wellcome Trust Sanger Institute, among others, measured over 500 blood metabolites of nearly 8,000 study participants. This effort revealed hundreds of exceptionally strong associations between metabolites and genetic variants. These associations provide a system-wide atlas of the effective activity of human genes and allelic differences, potentially improving disease understanding and providing new opportunities for drug development.
“One of the great conundrums in genomic research, aside from determining gene function, is to determine the biological meaning, if any, of allelic differences,” commented Michael Milburn, Ph.D., Chief Scientific Officer at Metabolon and one of two Metabolon authors to the publication. “Metabolic-allelic associations have the potential to provide a better understanding of gene function and can be enormously helpful in teasing apart genetic differences to improve biological understanding.”
“This study illustrates the power of discovery metabolomics to ‘complete the picture’ in human genomic studies aimed at understanding the complexity of human health,” said John Ryals, Ph.D, President and CEO of Metabolon. “The last decade of genomics research has revealed an even deeper level of complexity than once thought. Advanced metabolomics technology has the potential to bridge complex genetic and proteomic data to provide enhanced insight into the individual phenotype. We are grateful for the efforts of our long-term collaborators, Prof. Tim Spector, Prof. Karsten Suhre and Prof. Gabi Kastenmueller, for their leadership and dedication to this project. It is a tour de force of modern genomic and metabolomic research.”
Metabolon has several ongoing initiatives that utilize its proprietary metabolomics technology to advance genomics-based health research. These include strategic partnerships with Craig Venter’s new genomics initiative, Human Longevity, Inc., and the Global Genomics Group (G3). These collaborations demonstrate increasing awareness among scientific experts about the important role metabolomics can play in other forms of ‘omic’ research.
Metabolon, Inc. is a world-leading, commercial-stage metabolomics company whose expertise is embraced by the pharmaceutical, biotechnology, consumer product, agricultural, pet care and nutrition industries, as well as government and academic institutions. Founded in 2002, Metabolon has conducted more than 3,000 collaborative studies with more than 600 organizations. The company is pioneering the emerging field of global biochemical pathway analysis for biomarker discovery and development of innovative diagnostic tests. Its metabolytics business focuses on the measurement of small molecules involved in metabolism. This proprietary technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biological processes. Metabolon’s extensive metabolomics library has also led to the development of three novel, commercially marketed diagnostic tests targeting type 2 diabetes and prostate cancer. For more information, please visit www.metabolon.com.
Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove incorrect, the results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, among other risks, uncertainties and assumptions: the uncertainties inherent in biochemical research and development; our highly competitive industry; our ability to compete effectively; and our ability to continue to innovate and provide products and services that are useful to our clients.
Vice President, Corporate Marketing & Communications